英文名称:Gliclazide Modified Release Tablets 适应症:当单用饮食疗法,运动治疗和减轻体重不足以控制血糖水平的成人非胰岛素依赖型糖尿病(2 型)。 主要成分:本品主要成份格列齐特缓释片。 规格:60mg 相互作用:1.以下药品可能会增加低血糖的危险,禁止联合应用:咪康唑(全身途径,口服凝胶):增加降糖作用并可能会出现低...
GLICLAZIDE 60 MG MR TABLETS (Leaflet) Scheme Rec.INN ATC (Anatomical Therapeutic Chemical Classification) A10BB09 CAS registry number (Chemical Abstracts Service) 0021187-98-4 Chemical Formula C15-H21-N3-O3-S Molecular Weight 323 Therapeutic Category ...
Gliclazide modified release that has been recently launched by Servier (Uni Diamicron 30 mg) is a new formulation of gliclazide to be given once daily. The original hydrophilic matrix improves the biodisponsibility of gliclazide and allo... AJ Scheen - 《Revue Medicale De Liege》 被引量: 11...
Aim This study was to compare bioavailability of two gliclazide sustained release tablets in 18 healthy male volunteers and to evaluate the bioequivalence between the test and the reference tablets. Methods The study was conducted in the crossover, random, two-treatment, two-period design. RE-HPLC...
Gliclazide Modified Release Tablets English name: Gliclazide Sustained-release Tablets Chinese pinyin: Gelieqite Huanshi Pian 【Approval number】SFDA approval number H20063861 【Indications】Adult type 2 diabetes when diet alone, exercise therapy and weight loss are not enough to control blood sugar level...
Modified release tablets were reported to have an absolute bioavailability of 97% [26]. In situ micronization of GCZ using different stabilizers leads to quicker and thermodynamically stable dissolving crystals [6,27]. Nanocrystals and nanosuspensions (NS) were also reported [28,29]. Various ...
仿制药参比制剂数据库提供了格列齐特缓释片参比制剂的详细信息,包括英国上市名称:Gliclazide Modified Release Tablets的商品名Diamicron,英文名称Gliclazide Sustained-release Tablets,序号,规格,剂型,持证商Les Laboratoires Servier,目录分类等格列齐特缓释片参比制剂
Objective: A new spectrophotometric method for the gliclazide quantitation in dosage forms has been developed Material and Method: The subjects of the study were modified-release tablets ("Diaglizide" 80 mg, "Diaglizide MR" 60 mg, "Diaglizide MR" 30 mg, "Diabeton" MR 60 mg, ...
The final formulation contained 22 mg of Methocel®E15LV,16.5 mg Methocel®E15 and 10.0 mg of Dibasic Calcium Phosphate per 30mg Gliclazide sustained release tablet. Dissolution studies performed ontablets from 5000 tablet test batches released greater than 90 percent ofloaded drug in eight ...
J Control Release. 1985;1(3):269–82. Article CAS Google Scholar Appel LE, Zentner GM. Use of modified ethyl cellulose lattices for microporous coating of osmotic tablets. Pharm Res. 1991;8(5):600–4. Article CAS PubMed Google Scholar Shokri J, Ahmadi P, Rashidi P. Swellable ...